Summary of Q1 and Q2 2017 Accomplishments to Date:
Positive safety, tolerability and activity data through Cohort 3 of Phase 1 study of CLR 131 in multiple myeloma
Initiation of fourth cohort of Phase 1 study of CLR 131 in multiple myeloma
Initiation of NCI-supported Phase 2 clinical trial of CLR 131 in multiple myeloma and other hematologic malignancies
Consolidation of intellectual property portfolio for CLR 131 in multiple myeloma following license agreement with Wisconsin Alumni Research Foundation
Publication in Nature Reviews Clinical Oncology and presentation at Academic Surgical Congress, both regarding PDC platform
Additional intellectual property protection for CLR 131 in solid tumors in the US
Grant of US patent for CLR 124 in PET imaging
Additional US method of use patents for CLR 1501, CLR 1502 and an additional CLR 1401-boron-dipyrromethene analog for the detection of multiple cancer types
Japanese composition of matter patent for CLR 1501 and CLR 1502
Additional Japanese method of use patents granted for CLR 131 and CLR 125 in cancer stem cells
Appointment of John Friend as chief medical officer
Appointment of Doug Swirsky and Fred Driscoll to the Cellectar Board of Directors
“We continue to advance the clinical development of our lead product candidate, CLR 131, now in a fourth cohort of a Phase 1 trial for multiple myeloma, and an NCI-supported Phase 2 study in hematological malignancies. We have also successfully worked to enhance our intellectual property portfolio to protect the value in our pipeline,” said Jim Caruso, president and CEO of Cellectar Biosciences. “The additions to our management team and board underscore our commitment to progressing Cellectar strategically as we continue our clinical and preclinical development programs.”
